Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL\textsuperscript{PRO} and 3CL\textsuperscript{PRO} proteases

Dhananjay Jade\textsuperscript{a}, Selvaraj Ayyamperumal\textsuperscript{a}, Vyshnavi Tallapaneni\textsuperscript{a}, Chandrasekar Moola Joghee Nanjan\textsuperscript{b, *}, Sagar Barge\textsuperscript{c}, Surender Mohan\textsuperscript{d}, Moola Joghee Nanjan\textsuperscript{d, **}

\textsuperscript{a} Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, 643001, Tamilnadu, India
\textsuperscript{b} Biochemistry and Drug Discovery Lab, Institute of Advanced Study in Science and Technology, Paschim Boragaon, Guwahati, 35, Assam, India
\textsuperscript{c} School of Biotechnology, Laboratory of Molecular Biology and Genetic Engineering, JNU, New Dehi, 110067 India
\textsuperscript{d} JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, 643001, Tamilnadu, India

\textbf{ARTICLE INFO}

Keywords: SARS-CoV-2 COVID-19 PL\textsuperscript{PRO} 3CL\textsuperscript{PRO} Drug repositioning

\textbf{ABSTRACT}

The pandemic, COVID-19, has spread worldwide and affected millions of people. There is an urgent need, therefore, to find a proper treatment for the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the causative agent. This paper focuses on identifying inhibitors that target SARS-CoV-2 proteases, PL\textsuperscript{PRO} and 3CL\textsuperscript{PRO} which control the duplication and manages the life cycle of SARS-CoV-2. We have carried out detailed in silico Virtual high-throughput screening using Food and Drug Administration (FDA) approved drugs from the Zinc database, COVID-19 clinical trial compounds from Pubchem database, Natural compounds from Natural Product Activity and Species Source (NPASS) database and Maybridge database against PL\textsuperscript{PRO} and 3CL\textsuperscript{PRO} proteases. After thoroughly analyzing the screening results, we found five compounds, Bemcentinib, Pacritinib, Ergotamine, MFCD00832476, and MFCD02180753 inhibit PL\textsuperscript{PRO} and six compounds, Bemcentinib, Clofazimine, Abivertinib, Dasabuvir, MFCD00832476, Leuconicine F inhibit the 3CL\textsuperscript{PRO}. These compounds are stable within the protease proteins’ active sites at 20ns MD simulation. The stability is revealed by hydrogen bond formations, hydrophobic interactions, and salt bridge interactions. Our study results also reveal that the selected five compounds against PL\textsuperscript{PRO} and the six compounds against 3CL\textsuperscript{PRO} bind to their active sites with good binding free energy. These compounds that inhibit the activity of PL\textsuperscript{PRO} and 3CL\textsuperscript{PRO} may, therefore, be used for treating COVID-19 infection.

\section{1. Introduction}

In December 2019, rare pneumonia, now called COVID-19, that emerged in China, has spread worldwide and affected millions of people (Huang et al., 2020; Wang et al., 2020). This novel SARS-CoV-2 can infect many hosts, including swine, bats and humans. It is also capable of human-to-human transmission (Li et al., 2020). The virus is characterized by fever, dry cough, tiredness and affects people by producing mild or no symptoms to death (Huang et al., 2020). This is a fast-evolving virus derived from the characteristic high genomic nucleotide replacement rates and recombination (de Wit et al., 2016). Before the outbreak of COVID-19, the world was hit by two different viruses in 2002 and 2012, arising from the same family coronaviridae, namely Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Since then, the hunt for the treatment of coronavirus diseases has been going on, though not with success (Peeri et al., 2020; Chen et al., 2020).

Coronaviruses, the large single-stranded positive-sense ribose nucleic acid (RNA) viruses, consist of 27–31 kb viral genome (Chen et al., 2020; Zhou et al., 2020). SARS-CoV-2 belongs to the β-genus of the coronaviridae family and shares <80% nucleotide identity and 89.10% nucleotide similarity with SARS-CoV genes. These viruses produce ~800 kDa of polypeptide chain upon transcription (Fehr and Perlman, 2015). The polypeptide chain, when cleaved by the proteolytic enzymes, generates various proteins. This cleavage is mediated by the papain-like protease (PL\textsuperscript{PRO}) and 3-chymotrypsin-like protease (3CL\textsuperscript{PRO}) (Anand et al., 2003). PL\textsuperscript{PRO} cleaves the polyproteins at three sites, namely 181–182, 818–819 and 2763–2764, at the N-terminus and 3CL\textsuperscript{PRO}...
cleaves the polyproteins at 11 sites to generate various non-structural proteins that are important for viral replication. 3CL\textsuperscript{PRO} protease is believed to regulate the proteolytic processing of the two large viral replicase polyproteins, pp1a (450 kDa) and pp1ab (750 kDa), translated by the open reading frames (ORFs1a/b). The other ORFs at 3'-terminus encodes for the spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins (Chen et al., 2020; Zhou et al., 2020; Anand et al., 2003) (Fig. 1). The critical role played by PL\textsuperscript{PRO} and 3CL\textsuperscript{PRO} in replicating the virus, therefore, makes these two protease proteins potential targets for screening inhibitors for the virus, SARS-CoV-2 (Thiel et al., 2003; Ziebuhr, 2004; Ziebuhr et al., 2001). However, no inhibitor has been developed and approved by the FDA so far despite some efforts made in this direction recently (Ahmad et al., 2020; Kouznetsova et al., 2020).

Recently several vaccine candidates have been developed. Some of them, subjected to large scale clinical trials, are being administered in several countries (Dai and Gao, 2021). COVID vaccines which have been approved by different regulatory authorities for use are Comirnaty, Moderna COVID-19, Covishield, Sputnik V, CoronaVac, BBIBP-CorV, EpiVacCorona, Convidicea, JNJ-78436735, Covaxin and CoviVac (https://www.raps.org/). Questions, however, have come up regarding the mutation rates of SARS-CoV-2, which could lead to immune evasion. Studies have also suggested that the mutations in the target proteins of the COVID-19 can be associated with drug resistance and vaccine inefficacy (Silveira et al., 2021). But then, a vaccine is not the end-all of the pandemic. Efforts to develop more potent therapeutics for COVID-19 should continue. There is an urgent need, therefore, to find alternatives like an effective inhibitor to prevent or treat this infection (Kim et al., 2020).

Considering this urgent need to find effective approaches to prevent COVID-19, fast-track approaches are being made today (Stasi et al., 2020; Weglarz-Tomczak et al., 2020). The two proteases, PL\textsuperscript{PRO} and 3CL\textsuperscript{PRO}, which play an essential role in processing the polyprotein translated from the viral RNA, are considered to be essential for the survival and growth of SARS-CoV-2 (Kanjanahaluethai et al., 2007; Oostra et al., 2008; van Hemert et al., 2008; Béz-Santos et al., 2014, 2015). Considering the crucial roles played by PL\textsuperscript{PRO} and 3CL\textsuperscript{PRO} protease proteins, these proteins can be used as potential targets to control the SARS-CoV-2 life cycle’s duplication. In the present study, we downloaded the ZINC database (FDA compounds), Pubchem COVID-19 clinical trial compounds, NPASS, and Maybridge database natural compounds. After subjecting them to space filtering based on threshold physicochemical drug like properties, 2D similarity index and ADMET, we carried out virtual high throughput screening to develop inhibitors for SARS-CoV-2 proteases, PL\textsuperscript{PRO} and 3CL\textsuperscript{PRO}.

2. Materials and methods

2.1. Preparation of SARS-CoV-2 PL\textsuperscript{PRO} and 3CL\textsuperscript{PRO} protein structures

The structures of SARS-CoV-2 PL\textsuperscript{PRO} and SARS-CoV-2 3CL\textsuperscript{PRO} were retrieved from the protein data bank (PDB), PL\textsuperscript{PRO} PDB ID 6w9c and 3CL\textsuperscript{PRO} PDB ID 6lu7. The ligand and water molecules were removed from their structures. The protein structures were prepared by adding hydrogen atoms and energy minimization through UCSF Chimera molecular software (Pettersen et al., 2004).

2.2. pK\textsubscript{a} calculation

The protein stability and its conformation can be explained in terms of the ionizable residues’ perturbed pKa values. The protonation state for the titratable residues at pH 6.0 was assigned according to structure-based pKa calculations, performed with the H++ web server (version 3.1) (http://biophysics.cs.vt.edu/H++) (Anandakrishnan et al., 2012). PL\textsuperscript{PRO} and 3CL\textsuperscript{PRO} protein crystal structures obtained from the PDB, 6w9c (2.70 Å) and 6lu7 (2.16 Å), were used for the study. Three different dielectric constants were selected for the protein (ε\textsubscript{int} = 4, 10, and 20) to evaluate the results’ consistency.

2.3. Prediction of the active binding site

In PL\textsuperscript{PRO} (PDB structure 6w9c protein) there is no active site in the crystal structure. Its active sites were predicted through MetaPocket 2.0 meta server on the protein with five pockets threshold (Zhang et al., 2011). 3CL\textsuperscript{PRO} (PDB structure 6lu7 protein) contains a mechanism-based inhibitor N3 and hence this binding site was selected for our study.

2.4. Preparing the selected database compounds

DrugBank FDA only (https://zinc.docking.org/catalogs/dbfda/), FDA-approved drugs (via DSSTOX) (http://zinc.docking.org/catalogs/fda/), PubChem COVID-19 clinical trial compounds (https://pubchemdocs.ncbi.nlm.nih.gov/covid-19), Natural compounds from NPASS database (Zeng et al., 2018) and Maybridge database (http://www.maybridge.com) were used for the virtual high throughput screening against PL\textsuperscript{PRO} and 3CL\textsuperscript{PRO} protease proteins (Irwin and Shoichet, 2005; Sterling and Irwin, 2015). ZINC database has a wide range of compounds. We downloaded the FDA-approved drugs, FDA-approved PubChem COVID-19 clinical trial compounds (Kim et al., 2019), compounds from the NPASS database and Maybridge database in 2D, SDF format. All the selected compounds were converted to 3D, mol2 format using the molconvert tool of InsJChem, ChemAxon software (http://www.chemaxon.com) (Kumar et al., 2019) and hydrogen atoms

Fig. 1. SARS-CoV-2 genome containing 16 non-structural proteins (Nsp) organized in individual with polyprotein 1ab (PP1ab). Red (PL\textsuperscript{PRO}) and Blue (3CL\textsuperscript{PRO}) triangles show the cleavage sites of the protease.
were added through ChemAxon command line.

2.5. Calculation of physicochemical properties

The drug-likeness of the downloaded compounds were assessed through Rule of 3 (Jhoti et al., 2013) and the Rule of 5 (Pollastri, 2010; Lipinski et al., 1997). This property of space filtering is based on the threshold drug-like physicochemical parameters of the compounds, namely Molecular weight (MW), cLogP, Hydrogen Bond Acceptor (HBA), Hydrogen Bond Donor (HBD), Topological Polar Surface Area (TPSA), Aromatic Ring and Rotatable Bonds. InstiChem command-line software was used to calculate these physicochemical properties (http://www.chemaxon.com).

2.6. Compound screening using similarity Tc search

The hit compounds obtained from screening of the threshold physicochemical properties, were used for calculating the 2D similarity using ScreenMD (JCChem Suite, ChemAxon) (http://www.chemaxon.com), which is based on chemical fingerprints (Sharma et al., 2020; Kumar et al., 2019). Tc of the selected compounds was calculated and the compounds were ranked according to the Tc similarity score. We assumed a database compound as an analog if the Tc is ≥ 0.75. Using this criterion, we determined the similarities between reference PubChem COVID-19 clinical trial compounds with NPASS database and Maybridge database compounds. This was followed by ranking according to the compounds’ Tc values from the NPASS database and Maybridge database with significant similarities to the reference compounds. The similarity threshold (Tc ≥ 0.75) helped in the selection of similar compounds from the vast chemical space.

2.7. Absorption, distribution, metabolism, excretion and toxicity (ADMET) prediction

The selected hit compounds were subjected to computational predictions for exploring ADMET using DS-4.1 software. The prediction of ADMET properties is an important step in drug design and development (Han et al., 2019; Norinder and Bergstrom, 2006). Six mathematical models, such as plasma protein binding, human intestinal absorption (HIA), blood-brain barrier (BBB) penetration, Cytochrome P450 2D6 inhibition, aqueous solubility and hepatotoxicity were used to screen the compounds. The Toxicity Prediction by Komputer Assisted Technology (TOPKAT) model consists of mutagenicity, carcinogenicity, biodegradability and skin irritancy of the compounds.

2.8. Molecular docking

The selected FDA-approved drugs, PubChem COVID-19 clinical trial compounds, NPASS and Maybridge database compounds, were subjected to molecular docking using AutoDock Tools 4.6 (ADT) (Morris et al., 2009; Holt et al., 2008). Polar hydrogen was added to the protease protein, and charges were assigned through the Kollman charges database with significant similarities to the reference compounds. The similarity threshold (Tc ≥ 0.75) helped in the selection of similar compounds from the vast chemical space.

2.9. Compound selection based on clustering

After docking, the virtual compounds were further subjected to Clustering using ChemBioServer online tool based on the Hierarchical Clustering method (Karatzas et al., 2020). The hit compounds screened against PLPRO and 3CLPRO were used for Clustering through Soergel (Tc) Distance method and Ward linkage Clustering method. The top cluster compounds are considered as good hits and hence we selected the top one Clustering Threshold value.

2.10. Molecular dynamics (MD) simulation

GROMACS-4.6.5 was used for performing MD simulation (Abraham et al., 2015). Protein topology was generated using GROMOS96 54A7 force field (Schmid et al., 2011). PRODRUG was used to create topologies for the ligands (Schüttelkopf and Van Aalten, 2004). The complex structure was solved with simple point charge (esp 216) water by putting the protein-ligand complex in a triclinic box. The system was neutralized by adding Na+ and Cl- ions and relaxed through energy the minimization process. PME algorithm was used to estimate the electrostatic interaction. Initially, 1ns temperature and pressure equilibrium step was performed, followed by a 20ns production simulation. Using g_rms, g_rmsf, and g_gyrate, the root mean square deviation (RMSD), root mean square fluctuation (RMSF) and Radius of gyration (Rg) were calculated. The formation of hydrogen bonds between the protein and the ligand were determined and the secondary structures of the protein and the ligand-protein complex were checked using do_dssp program.

2.11. Calculating the free energy of binding usingMM-PBSA

The MD simulation trajectories were subjected to Molecular Mechanics energies combined with Poisson-Boltzmann (MM-PBSA) and the binding free energies (BFE) were calculated using the formula,

\[ \Delta G_{\text{bind}} = \Delta E_{\text{ele}} + \Delta E_{\text{vdW}} + \Delta G_{\text{polar}} + \Delta G_{\text{nonpolar}} - T \Delta S, \]

where, \(\Delta E_{\text{ele}}\) and \(\Delta E_{\text{vdW}}\) are electrostatic and van der Waals components, respectively, and \(\Delta G_{\text{polar}}\) and \(\Delta G_{\text{nonpolar}}\) are polar and non-polar components, respectively (Gehened and Ryde, 2015). T\(\Delta S\) is the temperature and entropic contribution towards BFE. BFE plays a significant role in drug discovery, giving a quantitative estimation of the ligand’s binding to the protein. We used the 20ns MD trajectory to calculate MM-PBSA by using the g_mmpbsa Tool (Kumari et al., 2014).

The interaction analysis and visualization of the protein-ligand complex were carried out through AutoDock ADT and PyMOL. Docking conformation and MD simulation results were generated using PyMOL and the 2D graphs of RMSD, RMSF, Rg along with the protein-solvent hydrogen bond interactions and protein-compound hydrogen bond interactions were generated using xmgrace.
Fig. 2. Crystal structures of SARS-CoV-2. (A) PL\textsuperscript{PRO} and (B) 3CL\textsuperscript{PRO}.

Fig. 3. Titration Curves for PL\textsuperscript{PRO} and 3CL\textsuperscript{PRO} protease structures with different Internal Dielectric is 4, 10, and 20.
to 10 and 20, different isoelectric points were obtained. The total charges obtained are shown in Fig. 3A. The isoelectric point of \(\text{3CL}\) is 5.45, the total charge is \(-2\) when Salinity is 0.15, External Dielectric is 80 and the Internal Dielectric was 4. When the Internal Dielectric was changed to 10 and 20 the different isoelectric points and total charges were obtained as shown in Fig. 3B.

### 3.3. Active site identification in \(\text{PL}\) and \(\text{3CL}\)

\(\text{PL}\) contains four domains, namely the thumb domain, the palm domain, the fingers domain, and the extended ubiquitin-like domain (Ubl) as shown in Fig. 2A (Baez-Santos et al., 2015). An active site, the catalytic triad site, is present between the palm and thumb domains, which contains CYS111, TRP112, HIS272, ASP286, GLY271, LEU162, ASP164, GLY271, TYR273, ASP302, PRO248, TYR264, TYR268 and THR301 (Arya et al., 2020; Kong et al., 2015; Baez-Santos et al., 2014). Fig. 4A shows the top five binding active sites.

\(\text{3CL}\) contains two chymotrypsin-like \(\beta\)-domains, domain-I (1–99 residues), domain-II (100–185 residues) and domain-III (201–303 residues) which contains an \(\alpha\)-helical structure (Fig. 2B). Domain-III and II are connected with a long loop having 185–200 amino acids. In Domain-I and II, the active site cleft is located along with the catalytic triad consisting of HIS41 and CYS145. The residues present in the loop connecting domain-I and II are VAL186, ASP187, ARG188 and GLN189 and the side-chain residues are HIS41, MET49 and MET165. Residues MET165, LEU167, GLN189, THR190 and GLN192, are present around domain-I and domain-II. Along with these, residues THR190, ALA191 and GLN192 also participate in the active site (Hsu et al., 2005; Li et al., 2016). Fig. 4B shows the top binding pockets for \(\text{3CL}\). We selected the active pocket 1 for our study.

### 3.4. Calculation of physicochemical properties

The 4182 FDA approved drugs and the 321 compounds from PubChem COVID-19 clinical trials were not subjected to property space filtering based on physicochemical property calculation because these are FDA approved drugs. NPASS database natural product compounds of 30925 and the Maybridge database compounds of 53344 were, however, subjected to physicochemical property calculation. The down-loaded 2D coordinates for all the compounds were converted to 3D coordinates. The selected compounds were then refined using the physicochemical threshold parameters. ChemAxon (command line) software was used to calculate the drug-likeness properties based on the Rule of 3 and Rule of 5. The results are given in Table S2.

Based on the physicochemical property threshold, the 30925 natural compounds from NPASS reduced to 9044 compounds and 53344 compounds from Maybridge database reduced to 24328 compounds. Calculated physicochemical properties are shown in Fig. S1 for the NPASS database and Fig. S2 for the Maybridge database. The red line shows the decided threshold boundary.

### 3.5. Compound screening using similarity tanimoto coefficient (tc)

Using PubChem COVID-19 clinical trial compounds as reference compounds, NPASS compounds (9044) and Maybridge compounds (24328) were screened to assess their inhibition potential against proteases \(\text{PL}\) and \(\text{3CL}\) and the similarity index were calculated to filter the most similar compounds to PubChem COVID-19 clinical trial compounds, using ChemAxon ScreenMD program. Based on this screening, 659 NPASS compounds with 0.75 Tc value (Fig. 5A) and 329 Maybridge compounds with 0.75 Tc value were selected for further study (Fig. 5B).

### 3.6. ADMET prediction

The selected 659 compounds from the NPASS database and 329 compounds from the Maybridge database were than analyzed using the ADMET descriptors of DS4.1. ADMET plot, obtained by plotting the ADMET_PSA_2D vs. ADMET_AlogP98, describes BBB penetration and HIA level for the compounds (Fig. 6). The HIA, plasma protein binding, Cytochrome P450 2D6 inhibition and hepatotoxicity along with BBB were calculated. The selected compounds that pass the ADMET properties have no toxicity.

### 3.7. Molecular docking

#### 3.7.1. Protease \(\text{PL}\)

NPASS compounds of 659, Maybridge compounds of 329 and all the FDA approval compounds of 4182 and PubChem COVID-19 clinical trial of 321 were subjected to docking. The binding energies (BE) for these...
compounds were calculated using the AutoDock tool and the selected compounds based on the decided cut-off value of $-6.00 \text{ kcal/mol}$ are shown in Fig. 7. The violet color line shows the cut off range.

3.7.2. FDA approved drugs

Based on molecular docking carried out for the 4182 FDA approved compounds, 1429 compounds were selected which showed BE more

Fig. 5. Calculation of Average Chemical Fingerprint (CF), Tanimoto 2D Similarity $T_c$ value. (A) Average CF Tanimoto value for NPASS database, (B) Average CF Tanimoto value for Maybridge database. The Red line shows the threshold value.

Fig. 6. The plot of $\text{ADMET}_\text{PSA}_2D$ vs. AlogP98 (the 95 and 99% confidence limit ellipses corresponding to the HIA and BBB models for ligands). (A) NPASS database, (B) Maybridge database.

Fig. 7. BE for virtual hit compounds. The violet line shows the cut-off range for the compounds selected. (A) FDA approved compounds, (B) PubChem COVID-19 clinical trial compounds, (C) NPASS database compounds and (D) Maybridge database compounds.
than and equal to $-6.00 \text{ kcal/mol}$ (Fig. 7A). From the 1429 compounds, the top ten compounds were selected for interaction study. Among these ten compounds, Troglitazone, Conivaptan, Differin, Erivedge and Ergotamine bind at a region near the thumb region slightly above the catalytic triad region. All the other compounds bind at the Catalytic triad region (Fig. 8). Imatinib, Differin and Erivedge form pi-stacking with HIS175. Conivaptan forms pi-Stacking with TYR171. pi-Cation interactions are formed by Imatinib, Troglitazone, Differin, Erivedge with HIS175. The residue ARG166 forms pi-Cation interaction with Conivaptan and Estradiol Benzoate. Differin and Ergotamine form salt bridges with HIS175. Conivaptan forms pi-Stacking with TYR171. pi-Cation triad region (Fig. 8). Imatinib, Differin and Erivedge form pi-stacking with TYR264. MFCD02180753 forms pi-cation interaction with TYR264 and HIS175. MFCD04123932 forms pi-stacking interactions with TYR264. MFCD02180753 and MFCD02679250 form pi-stacking interactions with TYR264. MFCD02180753 forms salt bridge with ASP164 and GLU167. BE, 2D structure, hydrogen bond and hydrophobic interactions are shown in Table S4.

3.7.3. PubChem COVID-19 clinical trial compounds

Based on the molecular docking carried out for the 321 PubChem COVID-19 clinical trial compounds, 57 compounds were selected with BE more than and equal to $-6.00 \text{ kcal/mol}$ (Fig. 7B). From the 57 compounds, top 10 compounds were selected for interaction study. Bemcentinib forms hydrophobic interactions with TYR154, ASN156, TYR171, VAL202 and hydrogen bonds with HIS73, ASN156, GLN174. Pacritinib, Doxycycline and Ketotifen form salt bridges with ASP164 and Imatinib forms salt bridge with GLU167. Niclosamide forms pi-stacking interactions with TYR264, Ketamine with TYR264 and Imatinib with HIS175. Niclosamide forms halogen bonds with THR301 and ASP302. All these selected compounds bind to the catalytic triad region except Imatinib (light pink) and Bemcentinib (gray color) which bind in between the thumb and catalytic triad region (Fig. 9). The BE, 2D structure, hydrogen bond and hydrophobic interactions are shown in Table S5 and the graphical binding interactions are shown in Table S6.

3.7.4. NPASS hit compounds

Based on molecular docking carried out for 659 compounds from the NPASS database, 387 compounds were selected having BE more than and equal to six $-6.00 \text{ kcal/mol}$ (Fig. 7C). From the 387 compounds, the top ten compounds were selected for interaction study. Vallesiachotamine and 19-(R)-Acetoxytabersonine form pi-stacking interactions with TYR264. Lyscamine, Heyneaninehydroxyindolenine form pi-cation interaction with TYR264 and HIS175.19-(R)-Acetoxytabersonine forms salt bridge with ASP164, ARG166, ASP302. Talpinine, Lyscamine form salt bridge with ASP164. Alstilobanine C, 3-Deoxy Nagilactone C and 3-Deoxy Nagilactone C form salt bridge with ARG166. Heyneaninehydroxyindolenine forms salt bridge with ASP76 and HIS175. The NPASS database compounds bind to the catalytic triad region as shown in Fig. 10. The BE, 2D structure, hydrogen bond and hydrophobic interactions are shown in Table S7 and the graphical representation of interactions is shown in Table S8.

3.7.5. Maybridge hits compounds

Based on the molecular docking carried out for 329 Maybridge compounds, 143 compounds were selected based on BE more than and equal to $-6.00 \text{ kcal/mol}$ (Fig. 7D). From the 143 compounds, the top 10 compounds were selected for interaction study. MFCD02180753 forms pi-stacking interaction with TYR264, hydrophobic interactions with LEU162, ARG166, TYR264, THR301 and hydrogen bonds with LEU162, ASP164, TYR264 and TYR273. MFCD02679250 form pi-stacking interactions with TYR264. MFCD00552607 forms pi-cation interaction with ARG140. MFCD00552607 forms hydrophobic interaction with LEU101, GLN122, and hydrogen bond with GLU124, LYS126, ARG140. The Maybridge database compounds bind to the Catalytic triad region as shown in Fig. 11. The BE, 2D structure, hydrogen bond and hydrophobic interactions are shown in Table S9 and the graphical representation of interactions is shown in Table S10.

The compounds docked in PlPro protease are present near to the catalytic triad and Palm region. We found the virtual hit compounds bind to this region and show interactions with different amino acids. Compounds which bind in the Catalytic triad region were selected and sorted out based on the clustering method.

3.7.6. Protease 3CLPRO

NPASS database compounds of 659, Maybridge database compounds of 329, all the 4182 compounds from FDA approved drugs and 321 compounds from PubChem COVID-19 clinical trial were subjected to docking. The BE for these compounds, calculated using AutoDock tool and the selected compounds based on the cut-off value by $-8.00 \text{ kcal/mol}$.

Fig. 8. (A) The ten docked potential inhibitors against SARS-CoV-2 PL\text{PRO} from the FDA approved compounds, (B) The 10 potential inhibitors bind to PL\text{PRO}, (C) The surface protein with ligands bound to the pocket.
mol are shown in Fig. 12. The violet color shows the cut-off range.

3.7.7. **FDA approved drugs**

Based on molecular docking for the 4182 FDA approved drugs, 1000 compounds were selected which showed BE more than and equal to −8.00 kcal/mol (Fig. 12A). From the selected 1000 compounds, the top ten compounds were selected for interaction study. Paritaprevir forms hydrophobic interactions with HIS41, LEU141, GLU166, and GLN189 and hydrogen bonds with PHE140, HIS164, GLU166. Nintedanib forms hydrophobic interactions with HIS41, ASP187, GLN189, and hydrogen bonds with GLY143 and GLU166. Imatinib, Nintedanib and Ergotamine form salt bridge with GLU166. Imatinib and Lifitegrast form the pi-stacking interactions with HIS163 and HIS41. Lifitegrast forms the salt bridge with ASP187. Nilotinib forms halogen bond with GLN189. All the ten compounds bind to the active site between Domain-I and Domain-II, near to the long loop that connect Domain-III with Domain-II (Fig. 13). The BE, 2D structure, hydrogen bond and hydrophobic interactions are shown in Table S11 and the graphical representation of interactions is shown in Table S12.

3.7.8. **PubChem COVID-19 clinical trial compounds**

Based on molecular docking carried out for the selected 321 PubChem COVID-19 clinical trial compounds, 48 compounds were selected having a BE more than and equal to −8.00 kcal/mol (Fig. 12B). From these 48 compounds, the top 10 compounds were selected for interaction study. Bemcentinib forms salt bridge with GLU166, hydrophobic interactions with HIS41, MET49, ASN142, MET165, GLU166, PRO168, GLN189 and hydrogen bonds with ASN142 and GLU166. Bemcentinib,
Imatinib, and Abivertinib form salt bridge with GLU166. Ozanimod shows pi-Stacking interaction with HIS41. Amiodarone forms hydrophobic interactions with MET165, GLN189, and hydrogen bond with GLU166. The selected ten compounds bind in the active site between Domain-I and Domain-II, near the long loop that connect Domain-III and Domain-II shown in Red color (Fig. 14). The BE, 2D structure, hydrogen bond and hydrophobic interactions are shown in Table S13 and the graphical representation of interactions is shown in Table S14.

3.7.9. NPASS database hit compounds

Based on molecular docking carried out for the 659 NPASS database compounds, 137 compounds were selected having BE more than and equal to −8.00 kcal/mol (Fig. 12C). From these 137 compounds, the top 10 compounds were selected for interaction study. Serpentine and 3-Hydroxyglyantrypine form pi-stacking with HIS41. Leuconicine F forms pi-Cation interaction with HIS41. The selected top 10 compounds bind in the region between Domain-I and Domain-II, near the long loop connected to Domain-III and Domain-II shown in red color (Fig. 15). The BE, 2D structure, hydrogen bond and hydrophobic interactions are shown in Table S15 and the graphical representation of interactions is shown in Table S16.

3.7.10. Maybridge database hits compounds

Based on molecular docking carried out for 329 Maybridge compounds, 96 compounds were selected with BE more than and equal to −8.00 kcal/mol (Fig. 12D). From these 96 compounds, the top 10 compounds were selected for interaction study. MFCD03407257, MFCD04123932, MFCD00604704, MFCD00116061, MFCD00832476 and MFCD04123470 form pi-stacking interaction with HIS41. MFCD03407257 forms hydrogen bond interactions with HIS41, GLY143, GLU166 and hydrophobic interactions with HIS41, GLU166, ASP187. The hit compounds bind in the region between Domain-I and Domain-II near
the long loop connected to Domain-III and Domain-II, shown in red color (Fig. 16). The BE, 2D structure, hydrogen bond and hydrophobic interactions are shown in Table S17 and the graphical representation of interactions is shown in Table S18.

Molecular docking studies confirmed that the hit compounds bind to the 3CL\textsuperscript{PRO} protease active site between residues 140–145 and residues 163–166. These compounds bind to the catalytic diad at HIS41, CYS145 and GLU166. The docking score for all compounds from the selected database is summarized in Tables S3–S18.

3.8. Clustering analysis

Clustering analysis re-ranks the compounds and generates a filtered new list of compounds from docking that rank high for the receptor PL\textsuperscript{PRO} and 3CL\textsuperscript{PRO} binding. The top of the cluster are considered as better hits.

3.8.1. PL\textsuperscript{PRO} clustering

We performed Clustering analysis using ChemBioServer online tool based on the Hierarchical Clustering using Soergel (Tc) Distance method and Ward Linkage clustering method. We found 10 Clusters for PL\textsuperscript{PRO} (Fig. 17A). We selected the top cluster, which contains 9 compounds. From these nine compounds, we selected five compounds based on MD simulation and free energy calculation.

3.8.2. 3CL\textsuperscript{PRO} clustering

In 3CL\textsuperscript{PRO} Clustering, we found eight clusters (Fig. 17B). We selected the top cluster, which contains 11 compounds. From these 11 compounds, we selected six compounds based on MD simulation and free energy calculation.
3.9. MD trajectory analysis and binding free energy calculation

The structural and conformational stability of the protein-ligand complexes were checked during the 20ns simulation by calculating three properties, namely RMSD, RMSF, and Rg. We also checked the hydrogen bond interactions between the protein and ligand and between the protein and solvent.

3.9.1. MD simulation for PL\textsubscript{PRO}

The selected top five PL\textsubscript{PRO} compound complexes were analyzed for 20ns simulation through RMSD, RMSF, and Rg (Fig. 18). RMSD analysis shows the difference in the protein backbone from the initial structure (0ns) to the final confirmed structure (20ns). The complexes C-a backbone values were calculated after 20ns to check the stability of the system. Fluctuations were observed during the 20 ns simulation. Fig. 18A shows the RMSD plot for the selected five PL\textsubscript{PRO}-compound complexes. All the five complexes show more or less the same fluctuation as the protein without the ligand. All the five complexes except Bemecentinib-PL\textsubscript{PRO} show RMSD values between 0.1 nm and 0.3 nm. Bemecentinib-PL\textsubscript{PRO} complex shows an RMSD value of more than 0.3 nm up to the end of the simulation. The RMSD result reveals that the PL\textsubscript{PRO}-hit compound complexes are stable throughout the 20ns simulation period.

PL\textsubscript{PRO} protease shows high RMSF in the loop, turns, and coils. The initial residues (0–75 residues) of the protein are not very stable. It shows fluctuation of more than 0.4 nm at 185–200 and 215–230 residues. Residues 262–275 show an increase in the RMSF value of less than 0.4 nm (Fig. 18B). All the five PL\textsubscript{PRO}-hit compound complexes have

---

**Fig. 15.** (A) The ten docked potential inhibitors against SARS-CoV-2 3CL\textsuperscript{PRO} from NPASS database compounds (B) Top 10 potential inhibitors bind to the 3CL\textsuperscript{PRO} protein near the long loop connected by domain-I and domain-II, (C) The surface protein with ligand bound to the pocket.

**Fig. 16.** (A) The ten potential inhibitors against SARS-CoV-2 3CL\textsuperscript{PRO} from Maybridge database compounds, (B) Top 10 potential inhibitors bind to 3CL\textsuperscript{PRO} protein near to the long loop connected by domain-I and domain-II, (C) The surface protein with ligand bound to the pocket.
almost similar RMSF patterns. RMSF results of the five complexes confirm their strong binding to PL PRO protease.

Rg analysis was performed to judge the level of compactness of protein and the PL PRO-compound complexes during simulations. Lower Rg values characterize the compactness of the protein (Fig. 18C). Rg value at the start of the simulation for all the five PL PRO-compound complexes increases between 2.35 nm and 2.40 nm up to 500ps. After 500ps, it shows a slight decrease and becomes steady up to 20000ps (20ns) simulation between 2.30 and 2.40 nm. A constant Rg value between 2.30 and 2.40 nm shows the protein’s constant compactness when compounds bind to the protein and show constant interaction during the simulation (Fig. 18C). The Rg results reveal that the selected compounds bind to PL PRO protein with good compactness.

The hydrogen bond interactions between PL PRO and the solvent (Fig. 18D) and between PL PRO-compound complexes (Fig. 18E) were also calculated. Hydrogen bond formations in PL PRO-compound complexes reveal that when the PL PRO-compound complex is simulated for 20ns, hydrogen bond formation is constant. The majority of the compounds form more than one hydrogen bond. The hydrogen bond between the protein and the solvent is constant between 540 and 640
3.9.2. MD simulation for 3CL<sub>PRO</sub>

The selected top six 3CL<sub>PRO</sub>-compound complexes were analyzed for 20ns MD simulation through RMSD, RMSF and Rg (Fig. 19). RMSD plot shows fluctuations in 3CL<sub>PRO</sub> and 3CL<sub>PRO</sub>-compound backbone. At the initial simulation up to 5ns all the six 3CL<sub>PRO</sub>-compound complexes show the same fluctuation between 0.1 nm and 0.2 nm (Fig. 19A). When we compare the 3CL<sub>PRO</sub> and 3CL<sub>PRO</sub>-compound complexes, Clofazimine shows the highest RMSD value which is more than 0.2 nm between 5 and 5.5ns time and after 15ns it shows a fluctuation of more than 0.2 nm up to end of the simulation (20ns). The RMSD results reveal that the six 3CL<sub>PRO</sub>-compound complexes are stable throughout the simulation.

All the 3CL<sub>PRO</sub>-compound complexes show almost the same RMSF value (Fig. 19B). The changes in the RMSF values may be due to the loop, turns, and coils. All the six complexes show the same pattern of RMSF, but in some regions they show slightly more or less RMSF values. The RMSF fluctuations of the six 3CL<sub>PRO</sub>-compound complexes reveal that compounds strongly bind to the 3CL<sub>PRO</sub> active site.

Rg for all the compound-3CL<sub>PRO</sub> complexes is between 2.18 nm and 2.31 nm (Fig. 19C). At the initial stage up to 10ns, it shows the same pattern. After that, each complex shows a different Rg value. Comparing the Rg value between the six 3CL<sub>PRO</sub>-compound complexes and the protein, a slightly lower Rg value is observed for all complexes except 3CL<sub>PRO</sub>-Abivertinib and 3CL<sub>PRO</sub>-Clofazimine. Rg values of all the complexes show the compactness of the protein when the compounds bind to the 3CL<sub>PRO</sub> and all the complexes are stable with good compactness.

We also calculated the hydrogen bond formations between 3CL<sub>PRO</sub> and the compounds in the complexes and between the protein and the solvent (Fig. 19D). Protein-solvent hydrogen bond formations are observed by the amino acids 580–650. The compounds that bind to the 3CL<sub>PRO</sub> form hydrogen bonds with the solvent in the 470–580 amino acid region in the entire 20ns simulation. When the compounds bind to 3CL<sub>PRO</sub>, an average of two hydrogen bonds are formed in the whole simulation (Fig. 19E).

3.10. Binding free energy (BFE) analyses

BFE calculation is an attractive and reliable approach to predict protein-ligand binding affinities in drug discovery processes. BFEs were calculated using MM-PBSA for the selected five PL<sub>PRO</sub> and six 3CL<sub>PRO</sub> protein-compound complexes and the data are shown in Table 1. The data reveal that all the complexes show negative BFE indicating the stability of the complexes and thus good affinity between the ligand and the protein. Among all the PL<sub>PRO</sub>-compound complexes, MFCD00832476-protein shows the highest BFE of −64.11 kJ/mol and Ergotamine shows the lowest BFE of −200.060 kJ/mol. Bemcentinib, MFCD00832476 and MFCD02180753 protein complexes show better van der waals energy of −133.533 kJ/mol, −144.428 kJ/mol and −157.661 kJ/mol, respectively and electrostatic energy of −67.779 kJ/mol, −97.818 kJ/mol and −4.705 kJ/mol, respectively, SASA energy of −13.151 kJ/mol, −13.318 kJ/mol, −13.784 kJ/mol, respectively. BFE of Ergotamine (−200.060 kJ/mol) shows good binding affinity.

Among the all 3CL<sub>PRO</sub>-compound complexes, MFCD00832476 shows the highest BFE of −158.657 kJ/mol and Abivertinib shows the lowest BFE of −301.367 kJ/mol. Bemcentinib, MFCD00832476 and Leucotrine F complexes show high van der waals energy of −162.502 kJ/mol, −209.214 kJ/mol and −130.32 kJ/mol, respectively and electrostatic energy of −233.925 kJ/mol, −24.103 kJ/mol and −260.961 kJ/mol, respectively and SASA energy of −17 kJ/mol, −17.7 kJ/mol, −12.425 kJ/mol, respectively. All the five PL<sub>PRO</sub> and the six 3CL<sub>PRO</sub> complexes show good BFE.

4. Discussion

COVID-19 epidemic has made experts to realize that our options today to treat this life-threatening disease are unfortunately very limited. In spite of considerable research efforts carried out, as of today...
Table 1
MM-PBSA Binding free energy for the five Pt\(^{\text{PRO}}\)-compound and six 3Cl\(^{\text{PRO}}\)-compound complexes.

| Compound                | Van der Waal energy (kJ/mol) | Electrostatic energy (kJ/mol) | Polar solvation energy (kJ/mol) | SASA energy (kJ/mol) | Binding free energy (kJ/mol) |
|-------------------------|------------------------------|------------------------------|--------------------------------|----------------------|-------------------------------|
| Pt\(^{\text{PRO}}\) Hit Compounds |                              |                              |                                |                      |                               |
| Bemcentinib            | -133.533                     | -67.779                      | 135.999                        | -13.151              | -78.464                       |
| Pacritinib             | -161.261                     | -5.222                       | 72.476                         | -13.373              | -107.380                      |
| Ergotamine             | -164.065                     | -278.233                     | 258.320                        | -16.082              | -200.060                      |
| MFCD00832476           | -144.428                     | -97.818                      | 191.451                        | -13.318              | -64.114                       |
| MFCD02180753           | -157.661                     | -4.705                       | 59.149                         | -13.784              | -117.001                      |
| 3Cl\(^{\text{PRO}}\) Hit Compounds |                              |                              |                                |                      |                               |
| Clofazimine            | -220.155                     | -7.036                       | 81.063                         | -19.471              | -165.599                      |
| Bemcentinib            | -162.502                     | -233.925                     | 180.432                        | -17.077              | -233.071                      |
| Abivertinib            | -244.313                     | -256.523                     | 221.044                        | -21.576              | -301.367                      |
| Dasabuvir              | -246.323                     | -22.167                      | 123.144                        | -20.809              | -166.156                      |
|                        | -209.214                     | -24.103                      | 92.367                         | -17.706              | -158.657                      |

(continued on next page)
no drugs have been approved by the FDA. Developing a new drug from preclinical identification to approval, however, takes nearly US$1000 million and 12 years of time. A few vaccines developed and approved by regulatory authorities are being administered in several countries. It is only proper, therefore, that the existing drugs and potential therapeutic compounds available in public domain are investigated based on detailed and thorough computational bioinformatic approach to repurpose them to treat COVID-19.

In the present study, we have carried in silico high throughput virtual screening of FDA approved drugs, COVID-19 clinical trial compounds, natural products from NPASS and Maybridge databases against PI\textsuperscript{PRO} and 3CL\textsuperscript{PRO} proteases which cleave the causative agent, SARS-CoV-2, to several non-structural proteins that are important for the viral replication. A few studies like the present one have been carried out by earlier investigators using only small numbers of compounds and limited step-by-step virtual screening techniques (Deep et al., 2021; Sajjan et al., 2021; Nejabat et al., 2021; Mitra et al., 2020). We believe that the present study is more detailed and thorough as it is based on subjecting the existing drugs/compounds to filtering threshold physicochemical drug like properties and 2D similarity index followed by ADME prediction, molecular docking, clustering, molecular dynamics simulation and binding free energy calculation. It may be pointed out here that BFE calculation is an attractive and reliable approach to predict the binding affinities in drug discovery processes, which some of the earlier investigators have not carried out thoroughly like the present study. The study has revealed that five compounds, namely MFCD00832476, MFCD02180753, Bemcentinib, Pacritinib and Ergotamine inhibit PI\textsuperscript{PRO} and six compounds, namely Bemcentinib, Clofazimine, Abivertinib, Dasabuvir, MFCD00832476 and Leuconicine F that inhibit 3CL\textsuperscript{PRO}, may be used for treating COVID-19. In particular, Ergotamine and Abivertinib are good leads for designing and developing drugs for COVID-19.

Funding

Authors Selvaraj Ayyamperumal (2019-5557/CMB-BMS) and Vyshnavi Tallapaneni [3/1/3(12)19-NCD II] wish to express their gratitude to the Indian Council of Medical Research for the award of Senior Research Fellowship.

CRediT authorship contribution statement

Dhananjay Jade: Conceptualization, Methodology, Software, Writing – original draft. Selvaraj Ayyamperumal: Conceptualization, Methodology, Software. Vyshnavi Tallapaneni: Data curation, Writing – original draft. Chandrasekar Moola Joghee Nanjan: Visualization, Investigation, Resources, Writing – review & editing. Sagar Barge: Software, Validation. Surender Mohan: Software, Validation. Moola Joghee Nanjan: Supervision, Visualization, Investigation, Writing – review & editing.

Declaration of competing interest

The authors declare no competing interests.

Acknowledgment

We thank JSS College of Pharmacy, Department of Pharmaceutical Chemistry, Ooty, Tamilnadu, India., Biochemistry and Drug Discovery Lab, Institute of Advanced Study in Science and Technology, Paschim Boragaon, Guwahati-35, Assam, India, for providing us with the resources and completion of our research.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ejphar.2021.174082.

References

Abraham, M.J., Murtola, T., Schulz, R., Páll, S., Smith, J.C., Hess, B., Lindahl, E., 2015. Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. Software 1, 19–25.
Ahamad, S., Kanipakam, H., Birla, S., Ali, M.S., Gupta, D., 2020. Screening Malaria-box ligands against Plasmodium falciparum 3D7. J. Mol. Struct. 1216, 206–207.

Anand, K., Ziebuhr, J., Wadhwa, P., Musters, J.R., Hilgenfeld, R., 2003. Coronavirus main proteinase (3clPro) structure: basis for design of anti-sars drugs. Science 300, 1763.

Anandhrajah, R., Aguilar, B., Onufriev, A.V., 2012. H++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomic modeling and simulations. Nucleic Acids Res. 40, W537–W541.

Arya, R., Das, A., Prunhal, V., Kumar, M., 2020. Potential inhibitors against papain-like protease of novel coronavirus (CoV-19) from FDA approved drugs. ChemMedChem.

Baez-Santos, Y.M., John, S.E.S., Mesecar, A.D., 2015. The SARS-coronavirus papain-like protease structure, function and inhibition by designed antiviral compounds. Antivir. Res. 115, 21–38.

Baez-Santos, Y.M., Mielech, A.M., Deng, X., Baker, S., Mesecar, A.D., 2014. Catalytic function and substrate specificity of the papain-like protease domain of mp3 from the Middle East respiratory syndrome coronavirus. J. Virol. 88, 12511–12527.

Chen, Y., Liu, Q., Guo, D., 2020. Emerging coronaviruses: genome structure, replication, and pathogenesis. J. Med. Virol. 92, 418–423.

Dai, L., Gao, G.F., 2021. Viral targets for vaccines against Covid-19. Nature Reviews Immunology 21 (2), 73–82.

De Wit, E., Van Doremalen, N., Falzarano, D., Munster, V.J., 2014. SARS and MERS: recent advances. Nat. Rev. Microbiol. 12, 89–95.

Deep Bhowmik, Sharma, Ravi Datta, Prakash, Amresh, Kumar, Diwakar, 2021. Coronavirus (SARS-CoV-2) and its main protease (3clPro) structure: basis for design of anti-sars drugs. Eur. J. Pharmacol. 173–664.

De Wit, E., Van Doremalen, N., Falzarano, D., Munster, V.J., 2016. Sars and Mers: recent advances. Lancet 388, 1378–1387.

Dey, S., Paul, A., Basu, A., Saha, D., Chakraborty, K., 2021. 3clPro and Plpro inhibitors: repurposing Fda-approved drugs. ChemRxiv.

Fei, R., Zhang, F., Liu, Z., Ma, Z., Wang, H., 2020. Overexpression of SARS-CoV-2 3CLpro in E. coli and characterization of recombinant protease. J. Mol. Biol. 515, 395–406.

Fehr, A.R., Perlman, S., 2015. Coronavirus: an overview of their replication and pathogenesis. Coronavirus. Springer.

Genheden, S., Ryde, U., 2015. The Mm/Pbsa and Mm/Gsma methods to estimate ligand-binding affinities. J. Cheminform. 7, 13.

Huang, F., Wang, S., Wang, L., Duan, F., Wu, J., Wang, D., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.

Irwin, J.J., Shoichet, B.K., 2005. Zinc 15 affinity docking and dynamics simulations studies. Eur. J. Pharmacol. 173664.

Jhoti, H., Williams, G., Rees, D.C., Murray, C.W., 2013. The autocatalytic release of a putative RNA helicase in SARS coronavirus. Biochemistry 52, 7395–7403.

Ji, L., 2020. In silico virtual screening of potential inhibitor for 3Cl-like protease of Novel Coronavirus (SARS-CoV-2): a novel structure-based design approach. Sci. Rep. 10, 10132.

Kumar, R., Jade, D., Gupta, D., 2019. A novel identification approach for discovery of 5-ligand binding motifs for ddG-rich DNA. PeerJ 8, e9965.

Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development environments. Adv. Drug Deliv. Rev. 23, 3–25.

Liu, M., Tu, W., Chen, C., Jin, L., Yang, R., Wang, Q., Zhou, S., Wang, B., Liu, L., Luo, Y., Liu, Y., Shao, G., Li, H., Tao, Z., Yang, Z., Deng, Z., Liu, B., Ma, Z., Zhang, Y., Shi, G., Lam, T.T.Y., Wu, J.T., Gao, G.F., Cowling, B.J., Yang, B., Leung, G.M., Feng, Z., 2020. Early transcription dynamics within translation in wuhan, china. Nat. Med. 26, 1199–1207.

Liu, M., Tu, W., Chen, C., Jin, L., Yang, R., Wang, Q., Zhou, S., Wang, R., Liu, H., Wong, J.Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Wei, Y., Shi, R., Li, H., Bai, J., 2020. Discovery of Potent Inhibitors of Plpro2 by Screening Libraries of Selenium-Containing Compounds. Bioinformatics 36, 2602–2604.

Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development environments. Adv. Drug Deliv. Rev. 23, 3–25.